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Percutaneous cholecystostomy placement in cases non-responsive or otherwise non-operable 
acute cholecystitis: a retrospective, descriptive and outcome analysis 
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Dr. Christo Kloppers, MMed (Surg), MPhil (Surg Gastro) 
Head of Acute Care Surgery 
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Department of Surgery 




Dr. Karan Gandhi 
Senior Registrar in General Surgery 
Groote Schuur Hospital 




Dr. Rimon du Plessis 
Intern 
Groote Schuur Hospital 
University of Cape Town 
rimonduplessis@gmail.com 
1.2. Purpose of the Study 
The primary aim of this research is to demonstrate the safety and efficacy, or lack thereof, of 
percutaneous cholecystostomy placement as a management option in patients with acute 
cholecystitis (AC), not suitable for cholecystectomy and not responding to best medical 
management. 
The secondary aim of this research is to investigate the feasibility and complexities of interval 
cholecystectomy in this cohort of patients, with respect to the conversion rate to open, operating 
time and performing a subtotal cholecystectomy. 
1.3. Background 
Acute cholecystitis is a complication of cholelithiasis (gallstones) and one of the most common 
admission diagnoses in Acute Care Surgery Units. The standard of care, according to the Tokyo 
Guidelines (1-4), for the management of acute cholecystitis, includes the immediate use of 
empiric antimicrobial drugs and index-admission laparoscopic cholecystectomy. A (>72 hour) 
delay between the onset of symptoms and presentation and initiation of medical care, as well 
as high operative risk patients are the two main reasons for diversion from this protocol of care. 
In the case of delay, the guidelines suggest the use of interval (six week) cholecystectomy as 
appropriate care.  
 
Index admission cholecystectomy in the setting of delayed presentation has been associated 
with increased morbidity. As inflammation of the gallbladder progresses, the tissues become 
more oedematous, with anatomic distortion and therefore increased difficulty in identifying 
important structural landmarks during LC. This difficulty increases the risk of operative 
complications, including bleeding and common bile duct injury, the most feared complication 
of LC. In addition to this distortion, adjacent surrounding organs may be involved in this 
inflammatory complex, thereby also being placed at risk of injury during dissection. In such 
circumstances, alternative methods of controlling disease progression may be necessary. 
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According to the Tokyo guidelines (1-4), AC can be classified into three grades of severity, 
namely mild (grade I), moderate (grade II) and severe (grade III). The grading system takes 
into account clinical and laboratory parameters, with organ dysfunction representing more 
advanced disease. Percutaneous cholecystostomy tube placement has been described as a 
method to achieve sepsis control in patients with severe AC, in which case LC may not be safe, 
owing to operative and high anaesthetic risk. The use of percutaneous cholecystostomy is well 
established in critically ill patients with acalculous cholecystitis and its safety and efficacy have 
been reported in many studies (5-11). Early LC has recently been shown to reduce the rate of 
major complications as compared to PC, even in high risk patients (15) 
 
The management of one subset of patients with acute cholecystitis remains unclear. This group 
comprises those with delayed presentation, in whom index-admission surgery is not advised, 
but who subsequently do not respond to best medical therapy. They have traditionally 
undergone urgent cholecystectomy but suffer higher rates of both morbidity and mortality (12-
14).  
 
In the current setting, patients often present with a delay since the onset of symptoms, rendering 
index-admission cholecystectomy unsafe. This problem is exacerbated by the lack of urgent 
operating theatre time, often with more urgent cases taking preference, thus delaying operative 
care beyond what is deemed safe by the Tokyo guidelines. The vast majority of patients are 
managed by interval cholecystectomy, leaving only the mentioned unresponsive subset. Recent 
reports have established the safety of the use of percutaneous cholecystostomy tube placement 
in patient groups that include this subset (severe sepsis, septic shock, local gallbladder rupture, 
progressive intolerant pain and persistent fever) (5-11). 
1.4. Methodology 
1.4.1. Study design 
An observational research project of cohort study type based on retrospective data collection 
and analysis. 
1.4.2. Study Setting 
The current setting refers to the Acute Care Surgery Unit at Groote Schuur Hospital, Cape 
Town.  All patients seen with recent onset (or recurrent) acute right upper quadrant (abdominal) 
pain, fever, nausea and localized tenderness are subjected to: 
• Routine blood investigations (full blood count, urea, creatinine and electrolytes, liver 
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function tests and serum lipase) and  
• Ultrasonographic imaging.   
The clinically suspected diagnosis of uncomplicated acute cholecystitis is confirmed by the 
presence of: 
• Leukocytosis, 
• Normal renal function, 
• Non-elevated serum lipase and  
• Gallbladder calculi, with gallbladder wall thickening, pericholecystic fluid and the 
presence of a sonographic Murphy sign.  
These patients are admitted to the unit on intravenous empiric antibiotics and analgesia. 
Those that respond to initial medical therapy (relief of pain, normalization of temperature and 
leukocyte count) are converted to oral antibiotics and discharged with a date for interval 
cholecystectomy (minimum of six weeks). Some patients that present early (within 72 hours 
of onset of symptoms) may proceed to expedited index-admission cholecystectomy. 
Non-responders to initial therapy (patients with persistent pain, fever and/or raised leukocyte 
count) are subjected to the placement of percutaneous cholecystostomy tubes. Patients that 
improve on this therapy retain their drainage tubes for a minimum of 10 days and are subjected 
to an interval cholecystectomy. Non-responders to tube placement are considered for tube 
replacement or urgent surgery. Antimicrobial therapy is altered in accordance with sensitivity 
studies on bile specimens taken at tube placement. 
 
1.5. Characteristics of the Study Population 
Participants are to be drawn from patients who have been managed for acute cholecystitis by 
the Acute Care Surgery Unit at Groote Schuur Hospital, as above. 
 
1.6. Patient selection 
The cholecystostomy cohort will include the last 37 patients (up until July 2016) who required 
the placement of a percutaneous cholecystostomy tube for non-responsiveness to best medical 
therapy as identified by the records of the Department of Radiology. The arbitrary date of July 
2016 is chosen to allow for sufficient time to have passed for an interval cholecystectomy to 
have been performed. This calculation is based on the Unit’s average waiting lists. The initial 
date will be set by the first person on the list. 
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1.7. Research Procedures and Data Collection Methods 
Data collection will be done in a retrospective manner from the following archives: 
• Radiology records 
• Ward admission book, ward F25, Groote Schuur Hospital 
• Department of Surgery notes and prescription charts in the hospital folders of identified 
participants 
• Laboratory records 
Data point values for the following variables will be collected: 
• Age 
• Gender 
• History of diabetes, steroid use, smoking, human immunodeficiency virus infection 
• Admission blood pressure, heart rate, temperature, full blood count, urea, creatinine 
and electrolytes, liver function tests and lipase levels 
• Initial sonographic findings (as above) 
• All antimicrobial use 
• All culture and sensitivity results 
• Number of cholecystostomy tube placements for each individual in cholecystostomy 
cohort 
• Mention of dislodgement, bleeding, bile leakage, obstruction, malposition or infection 
in cholecystostomy cohort 
• Duration of tube placement 
• Time between index admission and interval cholecystectomy 
• Total length of hospital stay (index and subsequent admissions) 
• Operative time (interval cholecystectomy) 
• Mortality 
 
1.8. Data Safety and Monitoring 
Data capture will take place in a data tool, which will take the form of a spreadsheet file and 
performed by the co-investigators. The computer file will only be available to the principal- 
and co-investigators. No personally identifiable data will be collected in the data tool.  All ages 
will be changed by an arbitrary numerical value that will only be known to the principal- and 
co-investigator (e.g. add/ subtract 5 from every patient age). Admission dates and length of 
stay will, likewise, be altered by a schema only known to the mentioned parties. Gender will 
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be replaced by sets of arbitrarily chosen strings. All analysis will be performed with the 
abovementioned changes corrected. 
A second copy of the file will be made on a digital versatile disk once a week. These copies 
will be kept in the archives of the Department of Surgery, where similar records are kept. The 
final computer file and data analysis notebook will similarly be kept in the mentioned archive 
for the purposes of retrieval of the data by interested parties who have fulfilled the necessary 
requirements to gain access to the data. 
 
1.9. Data Analysis 
Data analysis is performed using the GraphPad Prism software. 
(https://www.graphpad.com/scientific-software/prism). Descriptive statistics will include 
point estimates (mean, median, mode) and measures of dispersion (standard deviation, range, 
quantiles). Categorical variables will be analyzed by Fisher’s exact test, chi-squared test for 
independence (both with appropriate statistical parameter modification as appropriate) and 
non-parametric tests. Numerical variables will be analyzed by parametric and non-parametric 
test as indicated by quantile-quantile plots or by the Kolmogorov-Smirnov test for normal data 
distribution. A confidence level of 95% will be used and upper and lower bounds will be 
calculated by the method of bootstrapping. Unless otherwise indicated, a two-tail test 
hypothesis will be used with an alpha-value of 0.05 as discriminator for rejection of the null-
hypothesis. 
1.10. Description of Risks and Benefits 
This research poses no risk to the participants as all data will be collected in a retrospective 
manner.  
1.11. Informed Consent Process 
No specific informed consent will be required due to the observational, retrospective nature of 
the study. 
1.12. Privacy and Confidentiality 
See Data Safety and Monitoring above. 
1.13. Reimbursement for Participants 
Not applicable. 
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1.14. Emergency Care and Insurance for Research-Related Injuries 
Not applicable. 
1.15. End of Study 
This research project is intended for publication in a peer-reviewed journal.  A date for entrance 
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2. Literature review 
 
2.1. Literature Search Strategy 
A structured literature search was performed, using the PubMed electronic database 
(www.ncbi.nlm.nih.gov/pubmed). The search thread (acute cholecystitis) AND (percutaneous 
cholecystostomy) was used. Selected citations from the 404 articles that this search yielded 
were further reviewed. In addition, manual searches were performed for specific questions that 
were raised upon reviewing the literature. Non- English articles, duplicated articles and 
abstracts of conference proceedings were excluded. A total of 53 articles were included. 
 
2.2. Introduction 
Acute calculous cholecystitis (AC) is a complication of cholelithiasis (commonly known as 
gallstones) and one of the most common emergency surgical presentations. As the name 
suggests, it is an acute inflammation of the gallbladder, usually caused by an impacted stone 
in the cystic duct causing persistent obstruction. The bile stasis triggers a release of 
inflammatory mediators, with subsequent secretion of fluid into the gallbladder lumen- thereby 
causing further distension and inflammation. This is usually complicated by bacterial 
superinfection, via translocation from the gastro-intestinal tract. The vicious cycle of 
inflammation and distension can eventually lead to ischaemia, necrosis and perforation of the 
gallbladder (1). 
 
Diagnosis is based on clinical, laboratory and imaging parameters (2). Patients typically present 
with right upper quadrant abdominal pain and associated fever, nausea, anorexia and vomiting. 
The pain is persistent, as opposed to biliary colic where the pain is intermittent. Abdominal 
examination elicits localised peritonitis, evidenced by a positive Murphy’s sign (arrested 
inspiration due to tenderness on deep palpation) as the tip of the inflamed gallbladder comes 
into contact with the abdominal wall. Laboratory investigations usually reveal a neutrophil- 
predominant leukocytosis, with raised biliary ductal (alkaline phosphatase and gamma glutaryl 
transferase) enzymes, mostly in the absence of jaundice. The imaging modality of choice is 
ultrasound, which typically shows a distended, thick- walled gallbladder, pericholecystic fluid 
and a positive sonographic Murphy’s sign, usually with gallstones (1, 3). Gallstone disease in 
general, and therefore, AC usually affects females more commonly than males (4-6). 
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According to the Tokyo Guidelines (7-11), the standard of care for the management of acute 
cholecystitis is the use of empiric antimicrobial drugs and laparoscopic cholecystectomy (LC). 
 
Percutaneous transhepatic gallbladder drainage (PTGBD), otherwise known as percutaneous 
cholecystostomy (PC), is also described in the Tokyo Guidelines as an alternative to LC for 
sepsis control, in specific clinical settings of AC (7-9, 12). These include patients who are at 
high risk for anaesthesia, as well as critically ill patients or patients with severe (Grade III) 
cholecystitis. 
 
This literature review aims to narrate the history and evolution of acute cholecystitis and its 
management, which led to the current guidelines. It also aims to describe PC, and its technique, 
touching on safety, efficacy, complications and the natural history or typical clinical course 
once PC has been performed.  
 
2.3. History 
Dr. John S. Bobbs performed the first cholecystotomy (opening of the gallbladder, as opposed 
to stoma) on July 15th 1867. This was done inadvertently while he was searching for an ovarian 
cyst in a young female patient with a four year history of biliary colic. He closed the gall 
bladder after extracting multiple stones and placed it under the abdominal incision. He termed 
the procedure ‘Lithotomy of the gallbladder.’ The patient recovered well and lived longer than 
her surgeon (13). 
 
Dr. Marion Sims performed the first actual surgical cholecystostomy on April 18th 1878. He 
sewed an open gallbladder to the corner of an abdominal incision after extracting multiple 
stones and bile. The patient died 8 days later of massive internal haemorrhage. Theodore 
Kocher performed the first successful cholecystostomy two months later, in June 1878. After 
this, cholecystostomy became the standard operation for cholelithiasis (13). 
 
Dr. Carl Langenbuch performed the first successful cholecystectomy on July 15th 1882. He 
believed that the gallbladder itself produced the stones and that cholecystostomy was only a 
temporary solution, as the stones recurred. This procedure was met by a lot of controversy over 
the standard cholecystostomy. Cholecystectomy was, hence, less commonly performed until 
the early 1900’s, when it eventually replaced cholecystostomy as the definitive procedure (13). 
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The first PC was performed by Elyaderani and Gabriele, in 1979. The patient was a 72 year 
old female, admitted with obstructive jaundice in the setting of metastatic uterine carcinoma. 
She had an enlarged gallbladder with a mass in the head of pancreas. Her clinical condition 
was deteriorating due to sepsis (cholangitis) and she was unfit to tolerate any surgery. PC was 
hence performed, with pus aspirated from the gallbladder. The procedure was uncomplicated 
and the patient responded well, showing clinical improvement (14). 
 
Subsequently, PC was performed for AC with similar results (15, 16). Shaver et al further 
developed the procedure and performed it for patients with AC (17, 18). PC thus became 
recognised as a management alternative in patients unfit for cholecystectomy. 
 
Laparoscopy as a diagnostic or treatment modality or technique was being investigated since 
the early 1900’s, by a number of scientists. The experiments were initially largely performed 
on animal models and when this was translated to human patients, very few surgeons adopted 
or advocated for it. The dogma of ‘The bigger the cut, the bigger the surgeon’ held very 
strongly. The technique was accepted earlier by gynaecologists during the 1970’s, pioneered 
by German physician, Kurt Semm. When Semm performed the first laparoscopic 
appendicectomy in 1982, general surgeons began to pay more attention to laparoscopy, mainly 
for the threat or fear of losing more work to other physicians (19). 
 
The first laparoscopic cholecystectomy was performed on 12th September 1985, by Prof. Dr. 
Erich Mühe in Germany. He designed and used an instrument (in collaboration with Hans 
Frost, who worked for a German manufacturing company), that they called the Gallscope. The 
Gallscope could accommodate a full diseased gallbladder for delivery, had a valve to maintain 
pneumoperitoneum and instrument working channels with optics and a light conductor. The 
procedure was completed within two hours (19). 
 
Despite this apparent brilliance, Prof. Mühe’s work was met by strong resistance by the 
German Surgical Society and he was instead ignored and received strong criticism. He 
presented his findings on two separate occasions in 1986, but again received only skepticism. 
He submitted an article of the first LC to the American Journal of Surgery, which was rejected 
because of his difficulty with English (20, 21). 
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Laparoscopic cholecystectomy was later performed in France by Philip Mouret, on March 17th 
1987, by which time, Dr. Mühe had already performed 94 similar procedures. The patient was 
a 50 year old female, who was undergoing laparoscopic pelvic adhesiolysis and had 
symptomatic gallstone disease. The patient requested that her gallbladder be removed and, 
according to Dr. Mouret, the procedure was performed quite naturally and smoothly. The 
following day, the patient was found dressed and ready for discharge. She felt so well, that she 
thought her gallbladder hadn’t been removed as promised (20, 22). 
 
Philip Mouret’s technique was improved by Prof. Jacques Perrisat in 1988, and popularised 
since then. By 1993, the National Institutes of Health (NIH) declared it ‘the treatment of choice 
for many patients with cholelithiasis’ (23)(NIH consensus conference). By 2014, LC was 
declared the international gold standard for the treatment of symptomatic gallstones. 
 
It is worth mentioning, that the introduction of laparoscopic cholecystectomy marked a 
historical turning point for general and laparoscopic/ minimally invasive surgery. The 
procedure led to an explosion in the entire field of minimally- invasive surgery. Despite initial 
criticism and resistance, its rapid acceptance by both surgeons and the general population alike 
is unparalleled by any other surgical procedure in history. Patient demand was the most 
powerful driving force behind its evolution. 
 
In 1992, Prof. Mühe’s work was finally recognised and he received the German Surgical 
Society Anniversary Award, for ‘One of the greatest achievements of German Medicine in 
recent history.’ His contribution was recognised by the Society of American Gastrointestinal 
and Endoscopic Surgeons (SAGES) in 1992, and he was invited to give the Karl Storz lecture 
on new technology, in San Antonio. He titled his talk, The First Cholecystectomy: Overcoming 
the Roadblocks on the Road to the’ Future.’ 
 
In the shadow of all this rapid development of management strategies, surgeons quickly 
overlooked and forgot about the usefulness of cholecystostomy as an alternative, especially in 






2.4. Percutaneous Cholecystostomy 
2.4.1. Description 
Percutaneous cholecystostomy involves the placement of a drainage catheter (pigtail) into the 
gall bladder via skin puncture, strictly observing aseptic precautions. The procedure is 
performed under image guidance (ultrasound or computerised tomography (CT)) as well as 
under local anaesthesia and/ or procedural sedation. Fluoroscopy is used to confirm correct 
catheter position and technical success is defined as visualisation of the pigtail loop in the 
lumen of the gallbladder (24, 25). 
 
Two approaches are used to access the gallbladder, namely trans-hepatic and trans-peritoneal 
(26-28). In the trans-hepatic approach, access to the gall bladder is achieved via the bare area 
of the liver. This is the preferred route, according to published guidelines by the Tokyo group, 
mainly as it reduces the risk of bile leakage. It has the added benefit of enhanced catheter 
stability and faster tract maturation, however does carry the risk of other complications such as 
haemobilia and pneumothorax (28-30). Severe liver disease and coagulopathy are 
contraindications to using the trans-hepatic approach. Trans-peritoneal access may be difficult 
in patients with massive ascites or bowel interposed between the gallbladder and abdominal 



















Two techniques of PC have been described, namely the Seldinger technique and the trocar 
technique. The Seldinger technique involves needle puncture and gallbladder access 
confirmation by aspiration of bile. Once position is verified by contrast opacification, 
guidewire placement into the gallbladder follows. Subsequently the catheter is advanced over 
the guidewire and locked in position (24, 25, 31). The trocar technique  involves direct catheter 
placement into the gallbladder, over a sharp trocar or stylet. This would naturally have the same 
diameter as the catheter being inserted (24, 25, 31).  
 
The Seldinger technique has the advantage of using a fine needle, thereby reducing the risk of 
iatrogenic organ perforation and/or injury, while the trocar technique is faster due to the fewer 
number of manoeuvres. The trocar technique is also associated with a higher risk of bleeding 























2.4.3. Success rate/ efficacy 
The safety (low procedure-related complication rate) and efficacy (positive clinical response) 
of PC have been described in a number of studies(33-43). Early tube placement has been 
associated with fewer procedure- related complications and shorter hospital stay (44).  
 
Some studies conclude that PC can be used as definitive treatment for AC, in critically ill or 
frail, elderly patients who may never be candidates for surgery (36, 37, 43, 45-47). However, 
when compared in one study to LC (which is the gold standard of treatment), PC has been 
shown to have little benefit, even in critically ill patients. The authors of this study 
recommended that PC remain reserved for the specific group of patients who are not surgical 
candidates (48). Another comparative study performed, with a matched-pair analysis drew 
similar results and conclusions, stating that the only advantage of PC over LC was the reduced 
procedure duration (49). In addition to this, the lack of need for a general anaesthetic, in theory, 
renders PC advantageous. 
 
Technical success rates between 85- 100% are reported in various series (21, 36, 43, 50). 
Technical failure may be caused by factors that make gallbladder puncture difficult, like 
porcelain or thick- walled gallbladder. Other factors may include a heavy stone burden, or 
small gallbladder which does not accommodate the pigtail. Sedation and patient cooperation 
issues may also contribute to technical failure (24, 31). 
 
Positive clinical response is defined as improvement in patient symptoms, reduction in 
temperature and reduction in white cell count over 72 hours. A wide range of positive clinical 
response rates to PC have been reported in the literature (56- 100%). This variation is likely 
due to differences in patient populations, indications and clinical condition of patients at the 
time of PC (24).  
 
The value of PC as an alternative to treatment of AC in critically ill or unfit patients cannot be 
disputed (51). Most studies, however, are retrospective reviews and there remains a gap in the 
description of PC, its indications, complications and success/failure rates, by way of 





2.4.4. Complications/ Mortality 
Complications associated with PC can be divided into immediate, early (within the first few 
days) and delayed/late. Immediate complications include malposition/technical failure, 
pneumothorax, bile leakage, gallbladder rupture, peritonitis and haemorrhage. Inadvertent 
injury of an adjacent organ/hollow viscus may be an immediate complication, but might only 
be recognised within 24-48 hours. Early complications include drain dislodgement and 
haemobilia. Late complications include drain blockage, dislodgement, secondary sepsis, 
recurrent cholecystitis, abdominal wall abscess and non-healing of wound/tract (24, 50). 
 
The reported overall procedure-related complication rate of PC is low (< 1%), the most 
common being catheter dislodgement (21, 24, 29, 50). Pneumothorax is more common when 
using the transhepatic route, as the puncture site is higher up on the abdominal wall. Haemobilia 
is rare and bile leakage can range from asymptomatic, to pericholecystic abscess formation, to 
frank peritonitis requiring surgical intervention. Injury to adjacent organs is extremely rare, 
owing to imaging techniques and guidance. 
 
When compared with LC, patients who normally undergo PC are generally older, with more 
chronic illnesses. This relation can probably be attributed to the fact that these patients are less 
likely to tolerate LC, and hence PC is used for control of sepsis (calculous or acalculous AC). 
PC is associated with less complications than LC, but patients receiving PC are more likely to 
die, have increased hospital length of stay and hence increased cost (52). This is probably 
related to the comorbidities and patient clinical condition, rather than the procedure itself. 
However, as reported by a recent multicentre randomised superiority trial, LC has been shown 
to reduce the overall rate of major complications, even in high risk patients, when compared to 
PC drainage (53). 
 
To highlight this point, as described by a systematic review, the overall procedure- related 
mortality rate of PC itself is reported to be low (0.36%), with the overall 30- day mortality rate 
going up to 15.4% (21).  
 
 
2.5. Clinical course/ Natural history 
Once the diagnosis of AC has been made and the decision taken to perform PC, the procedure 
is performed using one of the techniques described above. Empiric antibiotic treatment is 
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usually commenced pre- procedure and is guided by local microbiology treatment protocols/ 
patterns. Gram negative cover is also necessary. Upon puncture of the gallbladder, bile/pus is 
aspirated and a sample sent for culture. Subsequent antibiotic treatment should be culture- 
directed (24, 25, 31).  
 
When technical success has been achieved, the drainage catheter is locked in position and the 
patient is monitored in the radiology suite for any of the immediate complications listed above. 
Once stable, the patient is transferred to the ward for further monitoring. Routine vital signs 
are monitored for assessing clinical response. The drainage catheter is flushed twice a day, with 
20ml of normal (0.9%) saline, to avoid blockage. Patients are monitored for any features of 
early complications. If there is no change in clinical condition within 72 hours, it is considered 
treatment failure and alternative methods of treatment should be considered. 
 
In uncomplicated cases with positive clinical response, patients may be discharged with the 
drainage catheter in situ. The importance of patient education and drain flushing cannot be 
overemphasised. There is no consensus for the duration of drainage, but it is based on the 
development of a mature tract and patency of the cystic duct. Tract maturation can be hindered 
by a variety of clinical conditions, such as uncontrolled diabetes, malnutrition, steroid therapy, 
ascites and sepsis (24, 25, 31). 
 
Trans-catheter cholangiography/check-cholecystography is performed at any time between 14- 
30 days (average tract - maturation duration), to asses cystic duct patency, the presence of 
stones in the common bile duct and formation of a mature tract. Provided that the cystic duct 
is patent and the tract matured, the drainage catheter can either be test-clamped, capped or 
removed. In cases of calculous cholecystitis, stone extraction or lithotripsy options may be 
considered due to the high rate of recurrence of AC (up to 33%). Recurrent attacks can be 
managed with repeat PC if necessary. If the patient is for permanent catheter drainage, 
replacement should be performed at three month intervals (24, 25, 31). 
 
2.6.  Question/ Problems 
There is no existing South African data on the use of PC for AC (at the time of submission of 
study protocol). Most literature is from international sources, and local practice is governed by 
international guidelines. The primary aim of this research is to demonstrate the safety and 
efficacy, or lack thereof, of percutaneous cholecystostomy placement as a management option 
22 
in patients with acute cholecystitis, not suitable for cholecystectomy, or not responding to best 
medical management. 
The secondary aim of this research is to compare these patients to a larger cohort of patients, 
similarly affected by acute cholecystitis, but who progressed favourably with best medical 
therapy and were ultimately managed by interval cholecystectomy. Conclusions may be drawn 
from the results, about the impact of PC on subsequent LC, in terms of procedure difficulties, 
time and conversion rates to open. 
This project may also stimulate consideration of potential for further research on the use of PC 
for AC in South Africa, and may highlight the potential need for a larger scale, multi- centre 
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Acute (calculous) cholecystitis (AC) is an extremely common surgical presentation, managed 
by cholecystectomy. Percutaneous cholecystostomy (PC) is a potential alternative.  However, 
its safety and efficacy, along with subsequent cholecystectomy, is under-reported in South 
Africa, where patients often present late and access to emergency operating theatre is 
constrained. The aim of the study was to demonstrate the outcomes of PC in patients with AC 
not responding to antimicrobials. 
 
Materials and Methods 
A retrospective review of patient records, who underwent PC in Groote Schuur Hospital, Cape 
Town, between May 2013 and July 2016, was performed. Patients with PC for malignancy or 
acalculous cholecystitis were excluded. Technical success, clinical response, procedure-related 
morbidity and mortality were recorded. Interval LC parameters were investigated. 
 
Results 
Technical success and clinical improvement was seen in 29 of 37 patients who had PC 
(78.38%). Malposition (3/37) was the most common complication (8.11%). Two patients 
required emergency surgery (5.4%), while one tube was dislodged. Median tube placement 
duration was 25 days (Range 1- 211). 16 patients (43.24%) went on to have LC. Eight required 
conversion to open surgery (50%). Four had subtotal cholecystectomy (25%). Median surgical 
time was 130 minutes (Range 60-300). There were no procedure-related mortalities. Eight 
patients (21.62%) died in the 90- day period following tube insertion. 
 
Conclusions 
PC is safe for patients with AC, with high technical success and low complication rate. 
Subsequent cholecystectomy should be performed, but is usually challenging. The requirement 









Acute cholecystitis (AC) is a complication of cholelithiasis and one of the most common 
admission diagnoses in Acute Care Surgery Units. The diagnosis is made according to criteria 
described in the Tokyo guidelines (4). According to the guidelines, the standard of care for the 
management of AC includes the immediate use of empiric antimicrobial drugs and index-
admission (otherwise known as hot) laparoscopic cholecystectomy (LC) (1-3). A (>72 hour) 
delay between the onset of symptoms and presentation and initiation of medical care, as well 
as high operative risk patients are the two main reasons for diversion from this protocol of care. 
 
In the case of delay, the guidelines suggest the use of interval (six week) cholecystectomy as 
appropriate care. High anesthetic risk patients or patients otherwise not suitable to undergo LC 
may be treated by the placement of percutaneous cholecystostomy (PC) tubes to allow drainage 
of the gallbladder (1-4). The use of PC is well established in critically ill patients with 
acalculous cholecystitis and its safety and efficacy have been reported in many studies (5-13). 
 
The management of one subset of patients with acute cholecystitis remains unclear. This group 
comprises those with delayed presentation, in whom index-admission surgery is not advised, 
but who subsequently do not respond to best medical therapy. They have traditionally 
undergone urgent cholecystectomy but suffer higher rates of both morbidity and mortality. 
 
In our setting, patients often present with a delay since the onset of symptoms, rendering index-
admission cholecystectomy unsafe. This problem is exacerbated by the lack of access to urgent 
operating theatre time, thus delaying operative care beyond what is deemed safe by the Tokyo 
guidelines.  The vast majority of patients are managed by interval cholecystectomy, leaving 
only the mentioned unresponsive subset. 
 
Recent reports have established the safety of the use of PC tube placement in patient groups 
that include this subset (severe sepsis, septic shock, local gallbladder rupture, progressive 
intolerant pain and persistent fever)(5, 8-11, 14-19). 
 
Anecdotally, it is generally accepted that laparoscopic cholecystectomy subsequent to PC 
placement is more difficult and challenging than that following simple AC. However, there is 
little data to support this entity and the degree of difficulty varies, as does the intra operative 
decision making. 
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3.2. Materials and Methods 
An observational, descriptive study was performed, based on retrospective data collection and 
analysis. Radiology records were reviewed, to identify and include potential participants for 
the study. The cohort included patients who underwent percutaneous cholecystostomy tube 
placement (PC) for acute calculous cholecystitis, at Groote Schuur Hospital between May 2013 
and July 2016. Patients who underwent PC for acalculous cholecystitis, malignancy or 
gallbladder perforation were excluded. Once the cohort was identified, patient folders were 
requested from medical records of the hospital for data collection and analysis. 
 
3.2.1. Ethical statement  
The study was performed according to a protocol approved by the Human Research Ethics 
Committee (HREC), of the Health Sciences Faculty, University of Cape Town, HREC Ref: 
526/2016. 
 
3.2.2. Data Collection 
Data collected included patient demographics, clinical and laboratory parameters on 
presentation, antibiotic choice, and imaging parameters. Procedure related complications, 
mortality, duration of tube placement and subsequent cholecystectomy parameters were also 
recorded and analysed. Data was captured by use of a google form and tabulated in the form 
of a spreadsheet file. Patient identifiers were removed and each patient was allocated a 
timestamp (based on time data was captured), to maintain confidentiality. 
 
3.2.3. Statistical Analysis 
Data is presented as median ± standard deviation. Statistical analysis was performed using the 




A total of 213 patients were treated at Groote Schuur Hospital with acute calculous 
cholecystitis (AC) between May 2013 and July 2016. Of these, 37 patients underwent 
percutaneous cholecystostomy (PC), due to failure of empiric antibiotic treatment. The other 





Figure 3: Outcomes of patients with acute cholecystitis (AC) treated at Groote Schuur Hospital between May 2013 and July 2016. 
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Figure 3 demonstrates the overall clinical progression and outcomes of patients managed over 
the study period. Data collected for the PC cohort included patient demographics, clinical and 
laboratory parameters on presentation (Table 1), imaging findings (Table 2) and eventual 
management. 
 
3.3.1. Basic Patient Characteristics:  
3.3.1.1. Demographics 
Of the 37 patients, 23 were female and 14 were male. Patient age ranged between 25 and 82 
years, with median age 54 years (Figure 4A and Table 1). At a glance, it would appear that 
females presented across a wider range of age groups compared to males (25- 82 years vs 50- 




















Figure 4: Patient demographics. A: Overall age distribution.  B: Age distribution stratified 
according to gender. Data presented as median with range. Statistical analysis in (B) performed 









































3.3.1.2. Clinical and laboratory parameters 
At presentation, systolic blood pressure ranged between 60 and 231 mmHg (median 120), with 
diastolic range between 20 and 108 mmHg (median 70) (Figure 5 and Table 1). Median heart 
rate was 100 beats per minute (range 60- 141), while median temperature was 370C (34.0- 
40.4). Median white cell count was 14.04 x109/L (range 1.96- 48.40) (Figure 5 and Table 1). 
Parameter PC Patients (n = 37) 
Age, median (range) ± SD 54 (25-82) ± 15.11 
Sex (M:F)  14:23 
Body Temp (oC), median (range) ± SD 37.00 (34-40.4) ± 1.46 
Blood Pressure (mmHg), median (range) ± SD  
Systolic 120 (60-231) ± 37.57 
Diastolic 70 (20-108) ± 37.57 
Heart Rate, median (range) ± SD 100 (60-141) ± 20.71 
White Cell Count (×109/L), median (range) ± SD 14.04 (1.96-48.82) ± 10.89 
Creatinine (µmol/L), median (range) ± SD 81 (40-507) ± 108.63 
γGT (U/L), median (range) ± SD 102 (15-1058) ± 262.45 





























Figure 5: Body temperature (A), white cell count (WCC) (B) and heart rate (beats per 



























































On ultrasonography, gallbladder wall thickening was found in 24 patients, while five scans 
demonstrated no wall thickening. The remaining eight scans had no mention of gallbladder 
wall thickness. Similarly, pericholecystic fluid was seen on 20 scans, while none was seen on 
eight scans and nine had no mention of presence or absence of fluid (Table 2). All patients had 
a positive sonographic Murphy’s sign. 
 
Table 2: Summary of ultrasound findings. 
 
 
Upon placement of drainage catheter, contrast cholecystogram (fluoroscopy) demonstrated 
cystic duct occlusion in 29 patients (78.38%). An example of this is demonstrated in Figure 6A 
below. Eight patients still had a patent cystic duct (21.62%) (Figure 6C). When trans-catheter 
check cholecystogram was subsequently performed (prior to drain removal), cystic duct 
patency was demonstrated in 23 patients (62.16%) (Figure 6D). Seven patients never had a 
check cholecystogram (18.92%), and the remaining seven had no cystic duct patency (Figure 
6E). A summary of all these findings is presented in Table 3. 
 
 





Ultrasonography Findings No. of Patients (n=37) 
Gallbladder wall thickening  
Present 24 
Absent 5 
No mention 8 
Pericholecystic fluid  
Present 20 
Absent 8 
No mention 9 
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Figure 6A: Insertion cholangiogram demonstrating a large stone in the gallbladder, with 
occluded cystic duct. B: Check cholecystogram for the same patient, demonstrating patent 
cystic duct, but persistent large stone in the gallbladder. C: Insertion cholangiogram 
demonstrating patent cystic duct with CBD stone. D: Check cholecystogram demonstrating 
patent cystic duct with good flow of contrast into the duodenum. E: Check cholecystogram 




Table 3: Summary of fluoroscopy findings. 
 
 
3.3.3. Complications and outcomes of Percutaneous Cholecystostomy 
3.3.3.1. Management 
Empiric antibiotic of choice was co-amoxiclav (local preference and protocol), which was 
administered to 26 of the 37 patients in our cohort (70.27%). For the rest of the patients, in 
whom amoxiclav was not used for a variety of reasons, local antibiotic stewardship guidelines 
were used to determine choice of empiric antibiotic. Technical success (correct placement of 
drainage catheter in the gallbladder lumen with clinical improvement) was achieved in 29 
patients (78.38%). Malposition (three) was the most common complication (8.11%) (Figure 
8). This was noted at the time of procedure for all patients, upon contrast opacification. These 
patients all went on to have a second attempt, which was successful. Two patients required 
emergency surgery (5.5%), while one tube was dislodged (Figure 7). The dislodged drain was 
not reinserted, as the patient demonstrated clinical improvement after initial drain placement. 







Fluoroscopy Findings No. of Patients (n=37) 
Insertion PC  
Cystic duct patent 8 
Cystic duct occluded 29 
Check cholecystogram   
Cystic duct patent 23 
Cystic duct occluded 7 

































Figure 8: Malposition of catheter, demonstrated by free contrast in the peritoneal cavity. The 






















There were no procedure-related mortalities, but eight patients (21.62%) died in the 90-day 
period post tube insertion (Figure 3). Of these eight, three deaths were due to progression of 
disease (37.5%), while five (62.5%) were due to co-morbid conditions. All three patients that 
died due to disease progression (worsening sepsis, with organ failure) were from the 
complication group - two with malposition and one with dislodgement. Of the other five 
patients that died, two had procedure-related complications, while three had successful PC. 
 
3.3.3.2. Follow up 
On follow up, 21 patients (56.76%) did not have definitive surgery (one due to diagnosis of a 
gallbladder carcinoma, eight due to death, seven due to anaesthetic risk, and five were lost to 
follow-up) (Figure 3). Of the seven anaesthetic risk patients, two had recurrent symptoms post 
drain removal, which necessitated second drain placement. The other five patients had no 
recurrence of symptoms. In the 16 patients who went on to have cholecystectomy (43.24%), 
high conversion rate (50%) and likelihood of subtotal cholecystectomy (25%) was 
demonstrated (Figures 3 and 9). The reasons for this high rate were not clear from the operative 
notes, but are thought to be due to inability to safely proceed with laparoscopic dissection and 
anatomical identification. Median surgical time was 130 minutes (Range 60- 300). In the cohort 
of patients who underwent cholecystectomy, median duration between tube placement and 






























Acute calculous cholecystitis (AC) can be divided into three severity grades; mild cholecystitis 
(grade I), moderate cholecystitis (grade II), and severe cholecystitis with organ failure (grade 
III), based on the Tokyo guidelines (2, 3, 20). It is one of the most common emergency surgical 
admission diagnoses. For patients that are fit for surgery, expedited index admission 
laparoscopic cholecystectomy (removal of the gallbladder) is the recommended treatment. In 
the South African setting however, patients often present late since the onset of symptoms, 
leading to progressive inflammation, sepsis or septic shock. Under these circumstances, it is 
thereby unsafe to perform cholecystectomy, as suggested by the Tokyo guidelines. Moreover, 
patient factors such as comorbidities and immunosuppression, coupled with the lack of access 
to urgent operating time, further adds to the difficulties in managing AC. Thus, the majority of 
patients receive interval cholecystectomy, after treatment with empiric antibiotics. 
 
Our study looked at a specific subset of South African patients attending a tertiary level hospital 
(Groote Schuur Hospital- GSH) with acute calculous cholecystitis, that did not respond to 
initial treatment with empiric antibiotics. This subset of patients underwent percutaneous 
cholecystostomy (PC) tube placement in an attempt to achieve source control and thereby treat 
cholecystitis. The safety of PC as a procedure to treat AC has been reported and established in 
the elderly and critically ill (15), and in other cohorts (16, 21, 22), but data is lacking in a South 
African setting. 
 
In our study population, the diagnosis of AC was made using a combination of clinical findings, 
laboratory parameters and imaging characteristics. Patients included in our study (that had PC 
catheter placement) presented with a wide range of vital signs. Temperature ranged from 
hypothermia to pyrexia, blood pressure ranged from hypertension to hypotension and shock 
and pulse rate ranged from normocardia to tachycardia. These findings are very non-specific 
and represent a wide spectrum of disease severity, in keeping with the grading system defined 
by the Tokyo guidelines (2, 3, 20). Owing to the retrospective nature of our study, we did not 
individually or collectively grade the disease severity in our patient cohort. Moreover, within 
the confines of the study, our criteria for PC drainage was not based on the clinical severity at 
presentation, but rather by lack of response to initial empiric antibiotic treatment. Perhaps this 
may be looked at as a limitation, and a correlation between disease severity and lack of response 
may be investigated further in a subsequent study. From this data, it is not possible to draw a 
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conclusion about predicting antibiotic treatment failure based on clinical severity (grade of AC) 
at presentation. While it is recommended that grade 3 cholecystitis is managed with PC 
placement as primary therapy, we feel that grade 1 and 2 cholecystitis should only require 
salvage PC placement in cases of antibiotic treatment failure. Similar comments can be made 
about the utility of white blood cell count in predicting the need for PC. 
 
Ultrasound findings diagnostic of cholecystitis include gallbladder wall thickening, presence 
of pericholecystic fluid and a positive sonographic Murphy’s sign, elicited using the ultrasound 
probe (23). Furthermore, the presence of gallstones is mandatory to label it ‘calculous’ 
cholecystitis. As reported by Pinto and colleagues, ultrasound remains the investigation of 
choice for diagnosis of AC (23). All patients in our study had gallstones and a positive 
sonographic Murphy’s sign on ultrasound. However, eight of the 37 ultrasound reports had no 
mention of wall thickness, while 24 patients had gallbladder wall thickening. The remaining 
five had wall thickness within normal limits. Similarly, pericholecystic fluid was seen on 20 
scans, while none was seen on eight scans and nine had no mention of presence or absence of 
fluid. Despite these obvious reporting shortfalls, the diagnosis of AC was made with 
confidence, after consideration of all available information at presentation. The usefulness of 
ultrasound for the diagnosis of gallstones and AC is unquestionable. While we cannot comment 
on its use to predict need for PC placement, we can certainly propose that a standardized 
reporting system be implemented and used, to reduce discrepancies in diagnosis of AC. 
 
Our study period extended over 38 months (between May 2013 and July 2016). During this 
period, there were a total of 213 patients admitted with AC. Of these, 176 were successfully 
treated either with hot cholecystectomy, or with empiric antibiotics (co-amoxiclav, based on 
our institute’s practice and policy) and interval cholecystectomy., The remaining 37 patients 
that did not respond to initial intravenous antibiotic therapy underwent PC tube placement. 
This demonstrates that a small proportion (17.37%) of all patients admitted with acute 
calculous cholecystitis actually required PC. This finding is supported in other clinical settings 
(24), which reported that 26% of AC patients (279/1072) received PC tube placement during 
the study period from October 2004 through December 2013.  Our findings also suggest that 
conventional therapy for AC is generally successful, as noted for 82.62% of patients in our 
study.  Similarly, (24) also found that ~74% of patients responded to hot cholecystectomy 
(42%) or antibiotic treatment (32%) as conventional therapy to treat AC. 
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Of the patients that underwent PC tube placement, 23 were female (62.2%), while the 
remaining 37.8% were male. This is unlikely to represent lower response to conventional 
treatment in females, but rather may be explained by the fact that in general, AC is more 
common in females than in males (25). Indeed, it is well known and documented that gallstone 
disease occurs more frequently in females than males (26, 27).  
 
The preferred route of placement at our institution is transhepatic, as opposed to 
transperitoneal, in keeping with the Tokyo guidelines (2, 3, 20, 28). Although bleeding (16, 
29) and an increased risk of pneumothorax and subsequent empyema (21) have been 
documented as complications with the transhepatic route, we did not observe any of these 
complications during procedure. This observation again, is similar to findings reported in other 
studies (10, 14). Interestingly, while some literature reports that the transhepatic route is 
preferred to the transperitoneal route (21, 30, 31), comparative studies have shown similar 
outcomes between the techniques (10, 29), stating that the choice between the two lies with the 
operator and on other factors, such as location of the gallbladder and patient body habitus, 
amongst others (32, 33). We remain neutral on this point as we did not make a comparison 
between the two approaches. 
 
The procedure was technically successful, with subsequent favourable clinical response post-
placement in 78% of patients (29), which is in accordance with success rates reported in other 
studies (14, 21, 22). Complication rates vary across studies for PC, ranging from 8%-10% (30, 
34), to 34% (21). Our results are comparable and fall within this range, as our overall 
complication rate was about 21.6% with malposition (three patients) being the most common 
complication followed by two patients needing emergency surgery. Altogether, this highlights 
that PC tube placement is a safe alternative, with low complication and high success rates, for 
treating AC in this group of patients. 
 
Upon access of the gallbladder via puncture, fluoroscopy is used to confirm site and correct 
position for subsequent catheter placement (35-37). Fluoroscopy can also give additional 
information regarding the status of the biliary ductal system. In this regard, review of 
fluoroscopy images from radiology records revealed that the cystic duct was occluded in 29 of 
our 37 patients (78.38%). These findings are in keeping with the pathogenesis of AC and also 
suggest that persistent cystic duct occlusion may be a predictor of failure of antibiotic 
treatment, which may necessitate PC placement. Conversely, the remainder of patients 
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(21.62%) had a patent cystic duct, suggesting that there may have been another cause for 
antibiotic treatment failure. However, the clinical significance of these points is questionable, 
as it is not rational or practical to obtain a cholangiogram for every patient presenting with AC, 
especially in a resource- constrained setting in South Africa. We would therefore recommend 
that the current, existing treatment guidelines continue to be followed. Similarly, check 
cholecystogram performed between 10-14 days after PC placement demonstrated cystic duct 
patency in 62.16% of patients. This is a significant change from the initial 21.62% patency 
rate. Contrast cholecystography was used to confirm cystic duct patency, prior to catheter 
removal, and is the standard practice at our institution. 
 
While there were no direct procedure-related mortalities, similar to previous studies (9), we 
documented eight mortalities (21.62%) in the 90-day period post-tube insertion. However, only 
three deaths (37.5%) were related to progression of the disease (all from the group that had 
procedure- related complications) whilst the majority, five deaths (62.5%), were due to co-
morbid disease (three of whom had successful PC). In comparison across clinical settings, our 
reported mortality rate for this study at GSH, South Africa, is fairly comparable to those 
previously reported at 0-25% (9, 22).  
 
Subsequent to PC placement, 16 patients underwent cholecystectomy. This highlights that PC 
can serve as an interceptive measure, or bridging therapy, for patients who are deemed 
surgically unfit at presentation. It also demonstrates that with this management, these patients 
can undergo an elective procedure later. Support for this is also documented in (14). In our 
cohort, eight patients (50%) had laparoscopic cholecystectomy, whilst conversion to open 
cholecystectomy was performed in the remaining 50%, with total and subtotal cholecystectomy 
representing 25% each. The high conversion rate (50%) is compatible with other studies where 
it has been documented at 45.5% (14). Once again, as earlier mentioned, data regarding the 
reason for conversion or subtotal cholecystectomy were not available. 
 
3.4.1. Conclusion 
The natural history of untreated AC is progression from inflammation and distension, to 
infection. Subsequently, as the cycle continues, gallbladder ischemia develops, followed by 
perforation. This leads to biliary peritonitis, which constitutes a surgical emergency. The same 
clinical course would ensue in AC not responding to antibiotic treatment. This clinical process 
has an associated morbidity and eventual mortality, thereby highlighting the need for sepsis 
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control. PC should, therefore, be reserved as a salvage procedure to achieve this in non-
responding patients to antibiotic therapy. Used in this scenario, it may be a life-saving 
definitive procedure for patients with high-operative risk. One should bear in mind though that 
the disadvantage of PC is that although the actual inflammation will likely settle, the causative 
agent (i.e. gallstones) remain and the patient remains at risk of future cholecystitis attacks. 
Anecdotally, it is accepted that the surgery after PC may be more technically challenging, but 
there is little data to support this. Furthermore, the degree of difficulty may also vary, as may 
the eventual procedure or bail-out operation. Our findings suggest similar challenges, but 
again, the numbers may not be large enough to substantiate this. Further study is required and 
warranted to provide supporting evidence. With that said, elective cholecystectomy should still 
be recommended following PC and clinical improvement.   
 
Taken together, while cholecystectomy remains the definitive management for symptomatic 
gallstones, PC can be viewed as a bridge to this definitive management. Our study, and those 
of others, have found PC to be safe for high-risk patients with AC, with high technical success 
and low complication rate. Subsequent cholecystectomy should be recommended, even though 
the surgery is usually challenging as mentioned above. This may be attempted laparoscopically 
bearing in mind that the conversion rate to open surgery, with bailout subtotal cholecystectomy, 
is high. In retrospect, the requirement for PC may serve as a surrogate predictor of AC disease 
process associated with suboptimal outcome. 
 
Health systems and the referral pathway in South Africa need to improve in order for patients 
to timeously reach a facility with appropriate levels of care. In addition, the availability of 
urgent operating theatre time should also be addressed. This would facilitate more patients 
undergoing early cholecystectomy, in keeping with the standard of care described in the Tokyo 
guidelines (1-4). Furthermore, early LC performed by a team of experts may help to improve 
outcomes in patients who present beyond 72 hours, up to a week, thereby reducing the need 
for bridging therapy with PC. 
 
Further research in the form of a prospective multicentre trial may be considered, to describe 
PC bridging and interval cholecystectomy, with key emphasis being placed on the surgical 
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